Short Bowel Syndrome Market was valued US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a XX% CAGR of around XX% during a forecast period.
Short bowel syndrome affect the functional ability of intestine. Patients suffering from short bowel syndrome have a decreased capability to absorb trace elements, vitamins, fats, fluids, minerals and carbohydrates and can experience weight loss, malnutrition, diarrhea and dehydration. Currently, there is no treatment for short bowel syndrome but the treatment is directed towards symptoms. In a rare cases, short bowel syndrome is life-threatening but usually, the disease can treated through effective medication. Treatment mostly comprises nutrition & diet management, medication and surgery. In treatment, Teduglutide was first permitted by the FDA for short bowel syndrome disorder and other treatments contain antidiarrheal, proton pump, inhibitors histamine blockers, and growth hormones.
The scope of the report includes a detailed study of global and regional markets for Short Bowel Syndrome with the reasons given for variants in the growth of the industry in certain regions.
Growing awareness and convenience of epidemiological data lead to the improved controlling of short bowel disease. Additionally, rapid developments in the field of healthcare have raised awareness about short bowel syndrome and thus, creates opportunities in future. Similarly, non-profit organizations are encouraging research & development about short bowel syndrome in joint scientific research among the public and private sector. In relationship with non-profit organizations, state governments offer special incentives to manufacturers for the improvement of short bowel syndrome drugs. The expansion of short bowel syndrome drugs is at an emerging stage, which generates more opportunities for global players. Public-private partnerships are inspiring pharmaceutical companies to improve new orphan drugs for short bowel syndrome. Few countries have executed a combination of legislations, regulations, and policies indorsing drug development for short bowel syndrome. These are the potential drivers for the growth of the short bowel syndrome market. Instead of this, a lack of sanctioned treatment options may lead to the down regulate the growth of short bowel syndrome market.
The report on Short Bowel Syndrome market covers segments such as by Drug Type, Distribution Channel and Region. The Drug Type segment includes Glucagon-like Peptide, Anti-Diarrheals, Histamine Blockers, Proton Pump Inhibitors, Growth Hormone, and Others. Among the Drug Type, Glucagon-like Peptide is accounted for the largest XX% share in the Short Bowel Syndrome market. Currently, Glucagon-Like Peptide is leading the market because of its wide presence in the U.S. and Europe. The Distribution Channel segment is further sub-segmented into Hospital Pharmacies, Specialty Pharmacies, and Others. Among the Distribution Channel, Hospital Pharmacies is accounted for the largest XX% market share in the Short Bowel Syndrome market. The Hospital Pharmacies from Distribution Channel segment is anticipated to have a reasonable growth during the forecasted period.
Based on regional segment, the Short Bowel Syndrome market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to dominate the market during forecasted period. The rising prescriptions for Glucagon-like Peptide treatment in the U.S. is anticipated to driver the growth for the North America short bowel syndrome market. Additionally, the fact that glutamine and growth hormone are only permitted in the U.S. for treating SBS is anticipated to keep North America in the lead. The increasing awareness about short bowel syndrome amongst consumers and outstanding reimbursement strategies are anticipated to fuel the regional market during forecast period.
Key players operating in the Short Bowel Syndrome market are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, Zealand Pharma A/S, Swedish Orphan Biovitrum AB, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca Plc, and Johnson & Johnson. The companies functioning in the market are concentrating on R&D investments and fund raising activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Short Bowel Syndrome market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Short Bowel Syndrome market.
for more information visit:https://www.maximizemarketresearch.com/market-report/short-bowel-syndrome-market/37257/
Scope of the Short Bowel Syndrome Market
Short Bowel Syndrome Market, By Drug Type
• Glucagon-like Peptide
• Histamine Blockers
• Proton Pump Inhibitors
• Growth Hormone
Short Bowel Syndrome Market, By Distribution Channel
• Hospital Pharmacies
• Specialty Pharmacies
Short Bowel Syndrome Market, By Region
• North America
• Asia Pacific
• Middle East & Africa
• South America
Key players operating in the Global Short Bowel Syndrome Market
• Ardelyx, Inc.
• Emmaus Life Sciences, Inc.
• GLyPharma Therapeutic, Inc.
• Merck KGaA
• Naia Pharmaceuticals, Inc.
• Nutrinia Ltd.
• OxThera, Sancilio & Company, Inc.
• Shire plc.
• Zealand Pharma A/S.
• Swedish Orphan Biovitrum AB.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• AstraZeneca Plc.
• Johnson & Johnson
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Name: Lumawant Godage
Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.
Address : Pune, Maharashtra 411051, India.